Prelude Therapeutics Inc
PRLD · Nasdaq · SIC 2834: Pharmaceutical Preparations
Business Summary
2 Item 1A. Risk Factors 23 Item 1B. Unresolved Staff Comments 76 Item 1C. Cybersecurity 76 Item 2. Properties 76 Item 3. Legal Proceedings 77 Item 4. Mine Safety Disclosures 77 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 78 Item 6. [Reserved] 78 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 79 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 89 Item 8....
Next Earnings
Q2 FY2026 — expected 2026-09-13
Key Facts from Earnings Calls
| Type | Subject | Detail | Quarter |
|---|
| topic_mention | PRLD | discussed_in_filing Cybersecurity | |
| topic_mention | PRLD | discussed_in_filing Cybersecurity | |
| topic_mention | PRLD | discussed_in_filing Cybersecurity | |
| topic_mention | PRLD | discussed_in_filing Cybersecurity | |
Annual Reports (10-K)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2026-03-10 | 2025-12-31 | 0001193125-26-099428 | EDGAR | 84K words |
| 2025-03-10 | 2024-12-31 | 0000950170-25-035921 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0000950170-24-016016 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0000950170-23-007989 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001564590-22-010723 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013330 | EDGAR | — |
Quarterly Reports (10-Q)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-275887 | EDGAR | 21K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108417 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064566 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122377 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095065 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053940 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057523 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037611 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018478 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024732 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028596 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019085 | EDGAR | — |
Recent Current Reports (8-K)
| Filed | Accession | Source | Full Text |
|---|
| 2026-03-12 | 0001193125-26-104204 | EDGAR | 1K words |
| 2026-03-10 | 0001193125-26-099424 | EDGAR | — |
| 2026-02-03 | 0001193125-26-034564 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008280 | EDGAR | — |
| 2025-11-12 | 0001193125-25-275871 | EDGAR | — |
| 2025-11-04 | 0000929638-25-004115 | EDGAR | — |
| 2025-10-17 | 0001193125-25-241968 | EDGAR | — |
| 2025-09-19 | 0001193125-25-208187 | EDGAR | — |
| 2025-08-14 | 0000950170-25-108413 | EDGAR | — |
| 2025-06-13 | 0000950170-25-086170 | EDGAR | — |
104 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers
Company Identity
| CIK | 0001678660 |
| Ticker | PRLD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: ab35126691f30bc458162bbaaf1fff0590c87d7a79f0ec8289e243af0409f065
parent: ad58ba5d78d2512a64e8c7cb79a87b802b690066d821b846f15ff7c10b7186a2
content hash: 52aeaeaad7c2f3a2568d6f79f655a06faa3b9a4f08258e5dda3fb4d4e2ae4e9c
signed: 2026-04-13T04:46:59.926Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf